PT  - JOURNAL ARTICLE
AU  - Daiana Stolz
AU  - Renaud Louis
AU  - Wim Boersma
AU  - Branislava Milenkovic
AU  - Kostantinos Kostikas
AU  - Francesco Blasi
AU  - Joachim Aerts
AU  - Gernot Rohde
AU  - Alicia Marin
AU  - Lucas Boeck
AU  - Janko Rakic
AU  - Andreas Scherr
AU  - Antoni Torres
AU  - Tobias Welte
AU  - Michael Tamm
TI  - COPD-specific co-morbidity test (COTE) for predicting mortality in COPD – Results of an European, multicenter study
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P566
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P566.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P566.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - BACKGROUND: The COTE index describes 12 comorbidities influencing survival in COPD. It reportedly complements the BODE index thereby improving its survival prediction. We hypothesize that prognostic systemic biomarkers in COPD (proadrenomedullin and copeptin) might be associated with the COTE index and could additionally improve survival prediction.METHODS: We prospectively evaluated 638 patients with stable COPD for ≥ 6 weeks, > 10 PY and GOLD II-IV seeking care in pulmonary tertiary hospitals in 8 European countries and included in the PROMISE cohort. Comorbidities and circulating biomarkers were assessed at baseline. The primary outcome of the study was death from any cause and from respiratory causes. Median observation time was 24 months.RESULTS: Coronary artery disease and liver cirrhosis presented the strongest association with mortality (p<0.01 for both). There was no association of the COTE index with an increase in the hazard of death (HR 1.060 95% CI 0.964-1.166). Stratification for the follow-up time (< 18 vs ≥ 18months) did not significantly influenced results. Time to death was similar in patients with low (1-3) or high (≥4) COTE index (p=0.364, log-rank). Results were unaffected by stratification for BODE quartiles. Neither proadrenomedulin nor copeptin differed in COTE strata (p=n.s for both). The AUC of proadrenomedullin and copeptin were higher than the one of the COTE index for mortality prediction at 2 years (0.648 and 0.609 versus 0.574).CONCLUSION: The COPD-specific co-morbidity test (COTE) did not contribute to assess mortality risk in patient with COPD. Neither proadrenomedullin nor copeptin are significantly associated with the COTE index.